E-LIB Suche - Ergebnisse für: Savage, K.

1

Impact of the Dark Zone Signature on Central Nervous System..:

Alduaij, W. ; Jiang, A. ; Collinge, B....
Hematological Oncology. 41 (2023) S2 - p. 294-296 , 2023

Link: https://doi.org/10.1002/..

2

15. The effect of hoof lesion score on sow survivability ov..:

Savage, K. ; Turpin, D.L. ; Clarke, T..
Animal - science proceedings. 14 (2023) 7 - p. 828-829 , 2023

Link: https://doi.org/10.1016/..

3

Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome ..:

Mutch, A. ; Lappin, K. ; Savage, K.
Leukemia Research. 128 (2023) - p. 107191 , 2023

Link: https://doi.org/10.1016/..

4

PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DA..:

Torka, P. ; Feldman, T. ; Savage, K....
Hematological Oncology. 41 (2023) S2 - p. 161-162 , 2023

Link: https://doi.org/10.1002/..

5

THE PROGNOSTIC IMPACT OF CLINICAL FACTORS AND IMMUNOARCHITE..:

Binkley, M. S. ; Flerlage, J. E ; Borchmann, P....
Hematological Oncology. 41 (2023) S2 - p. 100-101 , 2023

Link: https://doi.org/10.1002/..

6

PET‐Adapted Therapy with Nivolumab plus Adriamycin, Vinblas..:

Moskowitz, A. ; Savage, K. ; Feldman, T....
Hematological Oncology. 41 (2023) S2 - p. 351-353 , 2023

Link: https://doi.org/10.1002/..

7

CCTG LY18‐A phase I master protocol of novel combination th..:

Assouline, S. ; Villa, D. ; Hay, A....
Hematological Oncology. 41 (2023) S2 - p. 589-590 , 2023

Link: https://doi.org/10.1002/..

8

Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome ..:

Briggs, R. ; Savage, K. ; Lappin, K.
Leukemia Research. 128 (2023) - p. 107190 , 2023

Link: https://doi.org/10.1016/..

9

S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB..:

Hutchings, M. ; Ansell, S. M. ; Straus, D. J....
HemaSphere. 6 (2022) - p. 101-102 , 2022

Link: https://doi.org/10.1097/..

10

P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTO..:

Bachy, E. ; Savage, K. J. ; Huang, H....
HemaSphere. 6 (2022) - p. 1124-1125 , 2022

Link: https://doi.org/10.1097/..

11

S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN..:

Carlo-Stella, C. ; Ansell, S. ; Zinzani, P. L...
HemaSphere. 6 (2022) - p. 102-103 , 2022

Link: https://doi.org/10.1097/..

12

The ECHELON-2 Trial: 5-year results of a randomized, phase ..:

Horwitz, S. ; O'Connor, O.A. ; Pro, B....
Annals of Oncology. 33 (2022) 3 - p. 288-298 , 2022

Link: https://doi.org/10.1016/..

13

The Impact of Surveillance Imaging After Curative Intent Ra..:

Urban, R. ; Chow, R. ; Pickles, T....
International Journal of Radiation Oncology*Biology*Physics. 111 (2021) 3 - p. S105-S106 , 2021

Link: https://doi.org/10.1016/..

14

WHOLE GENOME SEQUENCING OF MATCHED PRIMARY AND RELAPSED DLB..:

Hilton, L. K ; Collinge, B ; Rushton, C. K...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

15

RITUXIMAB IN COMBINATION WITH BENDAMUSTINE OR HIGH‐DOSE CYT..:

Villa, D. ; Hoster, E. ; Hermine, O....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..